FDA grants approval for immunotherapy in breast cancer

Pinterest LinkedIn Tumblr

Biotechnology company Genentech recently announced the U.S. Food and Drug Administration approved Tecentric® plus chemotherapy as a treatment option for patients with PD-L1-positive, triple-negative metastatic breast cancer. The announcement marks the first immunotherapy regimen approved for breast cancer. (Genentech)

American Healthcare Journal is healthcare’s No. 1 source for the latest insights, news and analysis. An authoritative, digital-first and editorially independent publication committed to providing decision makers with unparalleled thought leadership and objective, industry-focused information to help them run their businesses in the new era of healthcare.